These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39203017)

  • 1. Preparation and Preclinical Evaluation of
    Cologni R; Holschbach M; Schneider D; Bier D; Schulze A; Stegmayr C; Endepols H; Ermert J; Neumaier F; Neumaier B
    Molecules; 2024 Aug; 29(16):. PubMed ID: 39203017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.
    Neumaier F; Zlatopolskiy BD; Neumaier B
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
    Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of novel PET tracers [
    Wang T; Lin Q; Zhang Y; Xu Z; Shi D; Cheng Y; Fu Z; Tan H; Cheng D; Shi H
    Bioorg Med Chem; 2022 Jan; 53():116525. PubMed ID: 34871844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours.
    Weber V; Arnaud L; Dukic-Stefanovic S; Wenzel B; Roux V; Chezal JM; Lai TH; Teodoro R; Kopka K; Miot-Noirault E; Deuther-Conrad W; Maisonial-Besset A
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosynthesis and biological evaluation of [
    Lai TH; Wenzel B; Dukić-Stefanović S; Teodoro R; Arnaud L; Maisonial-Besset A; Weber V; Moldovan RP; Meister S; Pietzsch J; Kopka K; Juratli TA; Deuther-Conrad W; Toussaint M
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1085-1096. PubMed ID: 37982850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
    Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study.
    Clément A; Zaragori T; Filosa R; Ovdiichuk O; Beaumont M; Collet C; Roeder E; Martin B; Maskali F; Barberi-Heyob M; Pouget C; Doyen M; Verger A
    Cancer Imaging; 2022 Mar; 22(1):16. PubMed ID: 35303961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of [
    Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
    Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
    BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
    Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
    Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
    Wang QX; Zhang PY; Li QQ; Tong ZJ; Wu JZ; Yu SP; Yu YC; Ding N; Leng XJ; Chang L; Xu JG; Sun SL; Yang Y; Li NG; Shi ZH
    Eur J Med Chem; 2023 Sep; 257():115464. PubMed ID: 37235998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
    Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
    J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.